To confirm the enhancement of the antitumor effect of IL 2 in the presence of MLT, concomitant administration of MLT and low dose IL 2 was carried out in patients with cancer who had progressed during previous immunotherapy with IL 2 alone, including 14 patients with advanced solid tumors, 6 with lung cancer, 4 with kidney cancer, 2 with stomach cancer, 1 with liver cancer, and 1 with melanoma dosage for tamoxifen
